Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Drug Pipeline Wins State Street Over on Healthcare

BY | ETF Database
12:54 pm ET 07/14/26 | 13 VIEWS
State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm’s Q3 2026 sector outlook upgraded healthcare from neutral to positive. That marks the sector’s return to State Street’s list of favored trades.Key Takeaways: Healthcare earnings could jump to 19.3% growth by 2027. Institutional investors remain underweight the sector despite recent buying. Valuations sit at their cheapest level in 15 years. Healthcare’s forward earnings multiple relative to the broader market has fallen to its bottom quintile over the past 15 years, according to the report. The sector’s earnings are projected to grow 19.3% in 2027, the second-highest rate of any sector behind technology. This upgrade follows a stretch of underperformance tied to drug-pricing uncertainty and slower medical procedure volumes. Many of those risks already appear priced into current valuations, State Street said. Investors can access this favored sector through the State Street Health Care Select Sector SPDR ETF (XLV A). Institutional flows into the fund category are near a five-year high over the past month, according to the report. That renewed interest comes from a low starting point. Health care remains underweight in many institutional portfolios, the report said. That leaves room for further buying if earnings trends hold up. See more: Not Just Tech: Invest in Innovation With Healthcare For investors looking for income alongside that exposure, State Street also offers the State Street Health Care Select Sector SPDR Premium Income ETF (XLVI ). The actively managed fund invests in shares of XLV and sells call options against it to generate additional income, according to the fund’s fact sheet. XLVI’s underlying exposure spans pharmaceuticals, health care equipment and supplies, biotechnology, health care providers and services, and life sciences tools and services, per the fact sheet. The fund carries a gross expense ratio of 0.35%.Biopharma Breakthroughs Fuel the Healthcare CaseDrug development is behind much of State Street’s optimism. Next-generation obesity treatments are showing weight loss along with improvements in heart-related risk factors, the report said. Alzheimer’s research is progressing too, with new methods aimed at helping drugs cross into the brain more effectively. Early gene-editing data also point to lasting reductions in cholesterol, according to the report. Cancer research added to the momentum. Presentations at the American Society of Clinical Oncology’s 2026 meeting covered progress in early-stage breast cancer and non-small cell lung cancer. Pancreatic cancer research also advanced, per the report. Managed care, a drag on the sector for months, is showing signs of steadying too. Growth in physician visits and medical procedures is no longer accelerating, State Street said, easing pressure on insurer margins. Risks haven’t disappeared. Policy uncertainty around drug pricing and managed care reimbursement remains an overhang, according to the report. Demand for medical technology also stays soft as procedure growth normalizes. Earnings growth for 2026 sits at just 2.6%, according to the report. The bigger jump comes in 2027, when biopharma innovation and steadier managed care trends could push growth above 19%. For more news, information, and analysis, visit our Sector Investing Content Hub.

More Commentary

Top Performing Leveraged/Inverse ETFs: 07/12/2026
BY | ETF Database
7:59 am ET 07/14/26 | 63 VIEWS
CLO ETFs: Recent Innovations
BY | ETF Database
8:57 am ET 07/14/26 | 23 VIEWS
SpaceX & Beyond: A New ETF for the Space Economy
BY | ETF Database
5:21 am ET 07/14/26 | 50 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.